Business Context and Reporting Period
Company: Champions Biotechnology, Inc. (also referred to as Champions Oncology, Inc. in metadata)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2009
Business Overview: The Company develops advanced preclinical platforms (Biomerk Tumorgrafts) and provides personalized oncology services. Revenue is derived from personalized oncology panels, tumorgraft development/testing, and preclinical eValuation services for pharmaceutical companies. The Company is a smaller reporting company with no debt.
Key Financial Metrics
| Metric | Nine Months Ended Jan 31, 2009 | Nine Months Ended Jan 31, 2008 | Three Months Ended Jan 31, 2009 | Three Months Ended Jan 31, 2008 |
|---|---|---|---|---|
| Total Revenues | $2,769,464 | $874,940 | $1,052,175 | $624,940 |
| Net Income (Loss) | $(1,022,306) | $174,011 | $(623,234) | $311,006 |
| Operating Expenses | $3,858,647 | $716,986 | $1,696,457 | $319,998 |
| Cash and Equivalents (End of Period) | $2,624,866 | $1,072,453 | $2,624,866 | $1,072,453 |
| Working Capital | $2,025,319 | $2,748,141 | $2,025,319 | $2,748,141 |
| Net Cash Used in Operating Activities | $(61,800) | $612,506 | N/A | N/A |
Liquidity: As of January 31, 2009, the Company held $2,624,866 in cash and cash equivalents and $1,005,319 in a certificate of deposit. Total current liabilities were $2,056,658, primarily consisting of deferred revenue ($1,361,110) and accounts payable ($695,548).
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 217% for the nine months ended January 31, 2009, compared to the prior year. This was driven by growth in Personalized Oncology services and the introduction of Preclinical eValuation services.
- Expense Surge: Operating expenses increased 438% year-over-year for the nine-month period.
- R&D: Increased from $75,000 to $1,144,010 due to platform building and drug pipeline development (SG410).
- Cost of Revenue: Increased from $264,262 to $1,824,089, including a $250,000 expense related to a joint Personalized Vaccine development agreement.
- G&A: Increased from $377,724 to $890,548 due to infrastructure expansion and public company compliance costs.
- Profitability Shift: The Company transitioned from a net income of $174,011 in the prior nine-month period to a net loss of $1,022,306 in the current period due to strategic investments in R&D and business development.
- Cash Flow: Operating cash flow turned negative, using $61,800 in the current nine-month period compared to providing $612,506 in the prior period. Investing activities used $1,043,653, primarily for the purchase of a certificate of deposit.
Guidance, Outlook, and Risks
- Outlook: Management states the Company has sufficient resources to fund operations for the next twelve months based on anticipated revenue growth and the ability to curtail spending. The Company intends to continue preclinical development of its lead candidate, SG410, with the goal of selling, partnering, or licensing it.
- Deferred Revenue: Deferred revenue increased significantly to $1,361,110, representing payments for services yet to be delivered, indicating a strong pipeline of future revenue recognition.
- Risks and Contingencies:
- Internal Controls: Management concluded that the system of disclosure controls and procedures was not effective as of the end of the period.
- Valuation Allowance: The Company maintains a full valuation allowance against its deferred tax assets ($2,831,800) due to uncertainty regarding the utilization of net operating loss carryforwards.
- Related Party Transactions: Revenue was recognized from Alfacell Corporation ($93,493) and ImClone Systems, Inc. ($125,686) for the nine-month period, where the Chairman serves as a director.
- Subsequent Events: Entered into a new operating lease in January 2009 for office and laboratory space commencing February 1, 2009, with an initial obligation of $66,000 for the first year.
Investor Verification Checklist
- Internal Control Deficiencies: Verify the specific nature of the ineffective disclosure controls and the remediation plan.
- Revenue Recognition: Confirm the timeline for recognizing the $1.36 million in deferred revenue and the stability of the underlying contracts.
- Burn Rate vs. Runway: Assess the sustainability of the current cash burn rate ($1.08M decrease in cash over 9 months) against the $3.6M total liquid assets.
- R&D Milestones: Monitor progress on the SG410 drug candidate and the Biomerk Tumorgraft platform to validate the heavy R&D spend.
- Related Party Dependence: Evaluate the concentration risk regarding revenue from companies where the Chairman has directorships.